Current status of antioxidant therapy for Alzheimer's disease

Journal of the American Geriatrics Society

Volumn 46, Issue 12, 1998, Pages 1566-1572

  Pitchumoni, Suresh S ^a   Doraiswamy, P Murali ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CATALASE; GINKGO BILOBA EXTRACT; GLUTATHIONE PEROXIDASE; RETINOL; SELEGILINE; SUPEROXIDE DISMUTASE; UBIQUINONE;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DRUG RESEARCH; HUMAN; LIPID PEROXIDATION; OXIDATIVE STRESS; REVIEW;

EID: 0031796122     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1998.tb01544.x     Document Type: Review

References (50)

1. Volicer L, Crino PB. Involvement of free radicals in dementia of the Alzheimer's type: A hypothesis. Neurobiol Aging 1990;11:567-571.
2. Halliwell B. Oxidants and the central nervous system: Some fundamental questions. Acta Neurol Scand 1989;126:23-33.
3. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994;344: 796-799.
4. Halliwell B, Gutteridge J. Oxygen radicals and the nervous system. Trends Neurosci 1985;8:22-26.
5. Frolich L, Riederer P. Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Drug Res 1995;45:443-446.
6. Joseph JA. The putative role of free radicals in the loss of neuronal functioning in senescence. Integr Physiol Behav Sci 1992;27:216-227.
7. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-147.
8. Fridovich I. The biology of the oxygen radical. Science 1978;209:875-877.
9. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994;36:747-751.
10. Benzi G, Moretti A. Are reactive oxygen species involved in Alzheimer's Disease? Neurobiol Aging 1995;16:661-674.
11. Ceballos-Picot I, Merad-Boudia M, Nicole A et al. Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type - Place of the extracellular glutathione peroxidase. Free Radic Biol Med 1996;20:579-587.
12. Connor JR, Menzies SL, Martin SM et al. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 1992; 31:75-83.
13. Gottfries CG, Bartfai T, Carlsson A et al. Multiple biochemical deficits in both gray and white matter of Alzheimer's brains. Prog Neuro-Psychopharmacol Biol Psychiatry 1986;10:405-413.
14. Zubenko GS. Hippocampal membrane alteration in Alzheimer's disease. Brain Res 1986;385:115-121.
15. Mason RP, Shoemaker WJ, Shajenko L et al. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging 1992;13:413-419.
16. Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 1990;55:342-345.
17. Kennard ML, Feldman H, Yamada T et al. Serum levels of the iron Protein p97 are elevated in Alzheimer's disease. Nat Med 1996;2:1230-1235.
18. Quinlan GJ, Halliwell B, Moorhouse CP et al. Action of lead (II) and aluminum (III) ions on iron-stimulated lipid peroxides on liposomes, erythrocytes, and rat liver mircrosomal fractions. Biochim Biophys Acta 1988;962:196-200.
19. Graham DG, Tiffany SM, Bell WR et al. Autooxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978;14:644-653.
20. Stacey NH, Kappus H. Cellular toxicity and lipid peroxidation in response to Mercury. Toxiocol Appl Pharmacol 1982;63:29-35.
21. Samokyszyn VM, Reif DW, Miller DM et al. Effects of ceruloplasmin on superoxide dependent iron release from ferritin and lipid peroxidation. Free Radic Res Commun 1991;12-13:153-159.
22. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with inreased dopamine turnover. Ann Neurol 1989;26:689-690.
23. Behl C, Davis J, Cole G et al. Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem Biophys Res Commun 1992;186(2):944-950.
24. Pellegrini-Giampietro DE, Cherichi G, Alesiani M et al. Excitatory amino acid release from rat hippocampal slices as a consequence of free radical formation. J Neurochem 1988;51:1961-1963.
25. Schor NF. Inactivation of mammalian brain glutamine synthetase by oxygen radicals. Brain Res 1988;456:17-21.
26. Behl C, Davis JB, Lesley R et al. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994;77:817-827.
27. Vinken, PJ, Bruyn GW, eds Handbook of Clinical Neurology, Vol. 31. New York: North Holland Publishing, 1977, pp 367-469.
28. Avraham KB, Schickler M, Sapoznikov D et al. Down's Syndrome: Abnormal neuromuscular junction in tongue of transgenic mice with elevated levels of human Cu/Zn-superoxide dismutase. Cell 1988;54:823-829.
29. Schickler M, Knobler H, Avraham KB et al. Diminished serotonin uptake in platelets of transgenic mice with increased Cu/Zn superoxide dismutase activity. EMBO J 1989;8:1385-1392.
30. Tohgi H, Abe T, Nakanishi M et al. Concentrations of α-tocopherol and its quinone derivative in cerebrospinal fluid from patients with vascular dementia of the Binswanger type and Alzheimer's type dementia. Neurosci Lett 1994;174:73-76.
31. Sano M, Ernesto C, Klauber M et al. Rationale and design of a multicenter study of selegiline and α-tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Dis Assoc Disord 1996;10:132-140.
32. Schneider LS. New therapeutic approaches to Alzheimer's disease. J Clin Psychiatry 1996;57:30-36.
33. Stahl, SM. Essential Psychopharmacology. London: Cambridge University Press, 1996, pp 137-139.
34. Laughton MJ, Halliwell B, Evans PJ et al. Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin: Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA. Biochem Pharmacol 1989;38:2859-2865.
35. Hara H, Kato H. Protective effects of alpha-tocopherol on ischemic neuronal damage in the gerbil hippocampus. Brain Res 1990;510:335-338.
36. Nelson JS, Fitch CD, Fischer VW et al. Progressive neuropathologic lesions in vitamin E deficient rhesus monkeys. J Neuropathol Exp Neurol 1981;40: 166-186.
37. Masaki KH, White LR, Petrovich H et al. The influence of prior and concurrent use of aspirin and vitamins on cognitive function scores in elderly Japanese-American men (abstract). Fourth International Conference on Alzheimer's Disease and Related Disorders. Neurobiol Aging 1994;15:S1.
38. Hendrie HC. Epidemiology of Alzheimer's disease. Geriatrics 1997;52:S4-8.
39. Dexter DT, Wells FR, Lees AJ et al. Increased nigral iron content and allerations in other metal ions occuring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
40. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328: 176-183.
41. Ben-Shlomo Y, Churchyard A, Head J et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levadopa and selegiline treatment in patients with early, mild Parkinson's disease: Further results of randomised trial and confidential inquiry. BMJ 1998;316:1191-1196.
42. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222.
43. Myers DG, Maloley PA, Weeks D. Safety of antioxidant vitamins. Arch Intern Med 1996;156:925-935.
44. Takahashi O. Haemorrhagic toxicity of a large dose of α-, β-, γ- and δ-tocopherols, ubiquinone, β-carotene, retinol acetate and L-ascorbic acid in the rat. Food Chem Toxicol 1995;33(2):121-128.
45. Le Bars PL, Katz MM, Berman N et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo Biloba for dementia. JAMA 1997; 1327-1332.
46. Packer L, Haramaki N, Kawabata T et al. Ginkgo biloba extract (EGb 761). In: Christen Y, Courtois Y, Droy-Lefaiz MT, eds. Effect of Ginkgo Biloba Extract (EGb 761) on Aging and Age-Related Disorders. Paris:: Editions Scientifiques Elsevier Paris, 1995, pp 23-47.
47. 2+-loaded brain neurons. Brain Res 1994; 635:125-129.
48. Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer's type, a double-blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol. 1994;9:215-222.
49. Kanowski S, Herrmann WM, Stephan K et al. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer's type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47-56.
50. Tesoriere L, D'Arpa D, Re R, Livrea MA. Antioxidant reactions of all-trans retinol in phospholipid bilayers: Effect of oxygen partial pressure, radical fluxes, and retinol concentration. Arch Biochem Biophys 1997;343:13-18.